YingLi Tian is a CUNY Distinguished Professor in the Department of Electrical Engineering at The City University of New York. Their work focuses on computer vision, machine learning, and medical imaging. Key areas include sign language recognition, medical image analysis, and AI-driven healthcare solutions. Research Interests: Artificial Intelligence applications in healthcare 3D point cloud and scene understanding Self-supervised learning and domain adaptation Sign language recognition systems Medical imaging segmentation and diagnosis Human-robot interaction and assistive technologies Notable Projects: Developed AI systems for American Sign Language recognition using RGB-D data Pioneered self-supervised feature learning techniques in medical imaging Created virtual contrast enhancement tools for CT scans Advanced sea ice motion prediction using deep learning Labs & Teams: Leads the Media and Information Technology Lab at CCNY, focusing on multimodal AI and healthcare technology innovations.
Prof. Dr. Helma Wennemers serves as a Full Professor at ETH Zurich's Department of Chemistry and Applied Biosciences, leading the Laboratory for Organic Chemistry. Her research group operates from HCI H 313 at Vladimir Prelog Way 1-5/10 in Zurich, Switzerland, with active teaching responsibilities including Organic Chemistry I and Chemical Biology - Peptides for the Fall 2025 semester. Her research program centers on the intersection of organic chemistry and chemical biology , with particular emphasis on collagen triple helix engineering , peptide-catalyzed asymmetric synthesis , and development of chemical tools for tissue remodeling diagnostics . Key focus areas include designing hyperstable collagen heterotrimers for fibrosis monitoring, creating fluorophore-based probes for collagen cross-linking visualization, and pioneering organocatalytic methodologies for complex heterocycle synthesis. Her group actively explores how hydrophobic modifications and proline derivatives influence collagen stability and cellular uptake mechanisms. Analysis of her 15 most recent publications (2024-2025) reveals three dominant research trajectories: (1) collagen structural engineering for biomedical applications, (2) innovative peptide/organocatalysis enabling stereoselective transformations, and (3) chemical probe development targeting tissue remodeling processes. These works consistently integrate synthetic chemistry with biological validation, demonstrating translational potential in fibrosis diagnostics and regenerative medicine. While specific grant details aren't provided in available sources, her research program clearly supports advanced laboratory infrastructure including peptide synthesis facilities and photochemical reaction systems like the ETHos photoreactor. Her group maintains strong industry and clinical collaborations evident in applications targeting liver cancer cells and prostate cancer diagnostics. The Laboratory for Organic Chemistry functions as an interdisciplinary hub where synthetic organic chemists collaborate with biologists to develop collagen-based diagnostic platforms and catalytic systems. Current projects focus on lysyl oxidase-responsive probes for real-time tissue monitoring and engineered peptide catalysts for sustainable chemical synthesis under environmentally relevant conditions.
Ji Hwan Park is an Assistant Professor in the School of Interactive Games and Media at RIT's Golisano College of Computing and Information Sciences (GCCIS). He holds a PhD from Stony Brook University under Prof. Arie Kaufman. His research focuses on accessible data visualization, digital twins, human-AI collaboration, and VR/AR applications. Notable contributions include developing tools for ADHD-friendly visualizations and interactive protein motif identification. He has received funding from the Department of Defense for biomedical research and earned an Honorable Mention at CHI 2024. Current teaching includes courses on game design and advanced algorithms. Research activities span medical imaging analytics (e.g., CMed framework for crowd-sourced diagnostics), climate modeling through Bayesian deep learning, and creative visualization techniques like Graphoto. His work bridges technical innovation with human-centered design principles, particularly in healthcare and neurodivergent accessibility contexts.
Paras N. Prasad is a SUNY Distinguished Professor with joint appointments in Physics, Chemistry, Medicine, and Electrical Engineering at the University at Buffalo. He serves as Executive Director of the Institute for Lasers, Photonics and Biophotonics (ILPB), which he founded in 1999. Dr. Prasad holds the Samuel P. Capen Chair of Chemistry and has pioneered interdisciplinary research at the interface of photonics, nanotechnology, and biomedicine. Education: BSc, Bihar University, India (1964) MSc, Bihar University, India (1966) PhD, University of Pennsylvania (1971) Postdoctoral Fellow, University of Michigan (1971-74) Research Focus: Dr. Prasad's multidisciplinary research spans photonics, nanophotonics, and biophotonics, with emphasis on nonlinear optical processes in nanostructured materials. His work develops photonic technologies for information processing, medical imaging, and cancer therapy through nanoparticle-based drug delivery systems and diagnostic platforms. The ILPB laboratory features state-of-the-art instrumentation for advanced optical research. Publication Trends: Recent articles demonstrate strong focus on nanomedicine applications, particularly cancer theranostics using functional nanoparticles. Key themes include drug delivery systems, chiral photonic materials, bioimaging technologies, and nanoparticle synthesis techniques. The research consistently bridges fundamental materials science with translational medical applications. Honors and Awards: SPIE Gold Medal (2016) IEEE Photonics Society William Streifer Award (2021) American Chemical Society Peter Debye Award (2018) OSA Michael Feld Biophotonics Award (2017) IEEE Pioneer Award in Nanotechnology (2017) Fellow of National Academy of Inventors (2016) Guggenheim Fellowship (1997) Leadership: As ILPB Executive Director, Dr. Prasad leads multidisciplinary teams developing photonic technologies with applications in healthcare, energy, and communications. His research has generated nine spin-off companies, including Nanobiotix currently in advanced cancer therapy trials.
John F Valliant is a Professor in the Department of Chemistry and Chemical Biology at McMaster University. His research focuses on radiopharmaceutical chemistry, molecular imaging, and targeted therapies, particularly in cancer diagnostics and therapeutics. He co-founded Fusion Pharmaceuticals, a company acquired by AstraZeneca for $2.4 billion (US), which specializes in targeted alpha therapy for cancer treatment. His work includes developing radiolabeled imaging agents for prostate cancer (e.g., [18F]DCFPyL), targeted alpha therapies (e.g., FPI-1434), and bioorthogonal chemistry strategies for pretargeted imaging. Valliant has contributed to advancements in photoacoustic imaging, SPECT/PET modalities, and theranostic agents for conditions like bacterial infections and bone diseases. Key projects include the Phase II clinical trial using 18F-DCFPyL PET-MRI for oligometastatic prostate cancer and studies on individualized dosimetry in Lu-177 therapies. He has pioneered platforms for radiolabeled antibody-recruiting molecules and fluorous-phase chemistry for high-specific-activity probes. Valliant’s research bridges disciplines, integrating chemistry, biology, and clinical applications to address unmet medical needs in oncology and diagnostic imaging.
Pingfu Fu, PhD, is a Professor in the Department of Population and Quantitative Health Sciences at Case Western Reserve University's School of Medicine. He is also a member of the Developmental Therapeutics Program at the Case Comprehensive Cancer Center. His expertise spans biostatistics, mathematics, and computer science, with a focus on cancer research and HIV/AIDS. Dr. Fu advises researchers on study design and statistical methodology for clinical and pre-clinical studies. He teaches courses in survival data analysis and clinical trials, and was recognized as 'Professor of the Year' in 2010 by the Department of Epidemiology and Biostatistics. Education: PhD in Biostatistics (Case Western Reserve University, 2001), MS in Statistics (Case Western Reserve University, 1996), MS in Mathematics (Xiangtan University, 1988), and BS in Mathematics (Jiangxi Normal University, 1984). His research interests include survival analysis, tree-based methods, clinical trials, and statistical applications in medical research. He has co-authored numerous peer-reviewed articles, focusing on cancer disparities, radiomics, and computational pathology. Professional memberships include the American Statistical Association, American Mathematical Society, and American Cancer Society. Dr. Fu holds editorial roles at Reviews on Recent Clinical Trials , Journal of Clinical Oncology , and Journal of the National Cancer Center . His work has addressed mathematical challenges in stochastic processes and resolved statistical issues in study design and tree-based models. Notable contributions include developing risk prediction models for cancer outcomes and advancing interdisciplinary collaborations across oncology, biostatistics, and computer science. His lab focuses on integrating computational methods with clinical data to improve patient outcomes.
Professor Ananya Choudhury serves as Chair and Honorary Consultant in Clinical Oncology at the University of Manchester, where she is also Co-Group Leader of the Translational Radiobiology Group within the Division of Cancer Sciences. She joined The Christie NHS Foundation Trust in 2008, specializing in urology and sarcoma, and has since focused on radiotherapy-related research in prostate and bladder cancers. Professor Choudhury is clinical lead for advanced radiotherapy, including the groundbreaking MRLinac project, and plays a key role in national radiotherapy research initiatives. Professor Choudhury earned her BA (Hons) in 1993, MB. BChir (Cantab) in 1995, and MA (Cantab) in 1997 from Trinity College, Cambridge. She completed her Clinical Oncology training at the Yorkshire Deanery from 2000-2008, during which she earned her MRCP in 2000 and F.R.C.R in 2004. She completed her PhD in 2008 through the University of Leeds and Princess Margaret Hospital in Toronto, Canada, where she studied the molecular epidemiology of DNA double strand break repair in bladder cancer. Professor Choudhury's research program focuses on optimizing and personalizing radiotherapy using advanced imaging technology to deliver high doses while minimizing side effects. Her work centers on prostate and bladder cancers, with particular interest in predictive biomarkers, hypoxia, and the integration of magnetic resonance imaging to improve treatment precision. She has pioneered research in radiotherapy dose optimization, biomarker development, and the identification of patients who would benefit most from different treatment approaches. Her extensive publication record demonstrates a strong focus on radiation therapy, particularly in genitourinary cancers. Recent work explores MRI-guided radiotherapy, hypoxia biomarkers, and personalized treatment approaches across multiple cancer types. She has made significant contributions to understanding how imaging technology can improve radiotherapy precision and effectiveness while reducing side effects, with several publications appearing in top journals through 2025. Professor Choudhury has received multiple prestigious awards recognizing her contributions to the field: Cancer Research-UK/Royal College of Radiologists Clinical Training Fellowship (2005) Fellowship for the 10th ECCO-AACR-ASCO Workshop on Methods in Clinical Cancer Research (2007) Outstanding Contribution, Greater Manchester Clinical Research Awards (2017) RCR Research Fellowship (2005) Research Fellowship, Princess Margaret Hospital, Toronto (2004) Professor Choudhury has supervised numerous doctoral and master's students across multiple cancer types, with current students expected to complete through 2024. She is Principal Investigator on multiple research grants, including 'Measuring tumour radioresistance to improve radiotherapy outcomes' and the 'MAESTRO Programme' as part of CRUK RadNet. Her research program is supported by significant funding from NIHR Manchester Biomedical Research Centre and other major funding bodies. As Co-Group Leader of the Translational Radiobiology Group, Professor Choudhury collaborates extensively with leading researchers including Peter Hoskin, Catharine West, Corinne Faivre-Finn, and Marcel van Herk. Her team is at the forefront of integrating advanced imaging with radiotherapy to improve cancer treatment outcomes, with active projects spanning from basic radiobiology to clinical implementation of novel radiotherapy techniques.
Weiyu Xu is a Professor at the University of Iowa, affiliated with both the Department of Electrical and Computer Engineering and the Department of Applied Mathematical and Computational Sciences. He joined the College of Engineering in 2012 and leads the Intelligent Information Processing Lab (IIPL). Ph.D., Electrical Engineering, California Institute of Technology, 2009 M.S., Electrical Engineering, California Institute of Technology, 2006 M.S., Electronic Engineering, Tsinghua University, 2005 B.E., Information Engineering, Beijing University of Posts and Telecommunications, 2002 His research focuses on compressive sensing, information theory, signal processing, network optimization, and deep learning applications in medical imaging and cybersecurity. He has made significant contributions to adversarial attack robustness, distributed optimization algorithms, and medical imaging techniques for OCT segmentation and brachytherapy. Recent publications highlight trends in Adversarial machine learning Medical imaging algorithms Compressed sensing for diagnostics Optimization in wireless communication He has also contributed to federated learning over tree networks and theoretical guarantees for sparse signal recovery. Weiyu Xu's lab, IIPL, integrates deep learning with classical optimization and signal processing. His work bridges foundational theories (e.g., information-theoretic robustness) with real-world applications in healthcare (e.g., cancer treatment planning) and communication systems (e.g., MIMO channel estimation).
Dan Nguyen, Ph.D., is a faculty member in the Department of Radiation Oncology at UT Southwestern Medical Center, where he is part of the Division of Medical Physics and Engineering. He is a founding member of the Medical Artificial Intelligence and Automation (MAIA) Laboratory, collaborating closely with Dr. Steve Jiang to advance AI applications in radiotherapy. His work focuses on deep learning for treatment planning, dose prediction, auto-segmentation, and adaptive radiotherapy. Ph.D. in Biomedical Physics, University of California, Los Angeles (UCLA), 2017 Mentor: Dr. Ke Sheng Faculty appointment at UT Southwestern since 2017 Dr. Nguyen’s research is centered on applying artificial intelligence to solve critical challenges in radiation oncology. His primary interests include deep learning-based dose prediction, auto-segmentation of anatomical structures, optimization of treatment plans, and real-time adaptive radiotherapy. He has pioneered work in direct aperture optimization, 4π radiotherapy, and uncertainty quantification in AI models. His research bridges the gap between AI innovation and clinical implementation, with a focus on improving plan quality, reducing planning time, and enhancing accessibility for less experienced clinicians. The most recent publications (2023–2025) demonstrate a consistent trend in developing fast, accurate, and robust deep learning models for radiotherapy. Key themes include dose prediction with transfer and meta-learning, adaptive segmentation using test-time optimization, uncertainty assessment in AI predictions, and mathematical modeling of radiotherapy-immunotherapy synergy. These works span high-impact journals in medical physics, AI, and oncology, reflecting interdisciplinary innovation. While no specific scientific awards are listed, Dr. Nguyen’s leadership in the MAIA Lab and extensive publication record in top-tier journals indicate significant recognition in the field of medical physics and AI in medicine. Dr. Nguyen has co-authored numerous studies involving mentoring and collaborative research, particularly with trainees and junior faculty in the MAIA Lab. His work is supported by institutional and likely federal funding, given the scale and scope of AI deployment studies. He has contributed to large-scale collaborative efforts such as OpenKBP-Opt, involving international teams evaluating knowledge-based planning pipelines. The MAIA Laboratory is a multi-investigator research group focused on innovating, developing, and applying artificial intelligence technologies to empower clinicians—especially those with less experience or limited resources—for improved patient care. The lab’s work spans machine learning, deep learning, reinforcement learning, and mathematical modeling in radiation oncology.
Ghassan AlRegib is the John and Marilu McCarty Chair Professor in the School of Electrical and Computer Engineering at Georgia Institute of Technology. He directs the Omni Lab for Intelligent Visual Engineering and Science (OLIVES), the Center for Energy and Geo Processing (CeGP), and previously led Georgia Tech's MENA initiatives (2015-2018). His research spans machine learning, image processing, and seismic interpretation with real-world applications in autonomous vehicles, medical imaging, and subsurface analysis. His research focuses on trustworthy AI systems through three pillars: enhancing interpretability, improving robustness/generalizability, and tackling domain-specific challenges. Key interests include human-in-the-loop frameworks, uncertainty quantification, explainable AI, and physics-driven learning. The OLIVES lab pioneered modern machine learning applications in seismic interpretation and developed open-source datasets for geological fault analysis. Dr. AlRegib's scientific contributions include over 270 publications, multiple U.S. patents, and leadership roles as Technical Program co-Chair for ICIP 2020/2024. His work demonstrates significant impact through awards like the IEEE Fellow designation (2022) and multiple best paper awards at premier conferences. IEEE Fellow (2022) 2023 EURASIP Best Paper Award 2019 ICIP Best Paper Award 2017 Denning Faculty Award for Global Engagement CSIP Research & Service Awards (2003) He has advised numerous PhD students including Dr. Ashraf Alattar (now Auburn professor) and Dr. Zhiling Long (Kennesaw State faculty). His lab structure emphasizes collaborative teams comprising postdocs, senior/junior PhD students, and undergraduates working on high-impact problems from autonomous systems to medical diagnostics. Current research thrusts include trustworthy neural networks, human-in-the-loop frameworks, and deployment of machine learning in seismic interpretation and ophthalmology.
Professor Ravi Shukla is a faculty member at RMIT University's School of Science, holding the title of Professor and Deputy Head of Department (Research). He specializes in Nanobiotechnology, with research spanning biomaterials, drug delivery systems, and medical diagnostics. His work integrates biosciences, materials science, and food technology to advance understanding of nanomaterial-biomolecular interactions. Academic History: Professor Shukla has held roles at RMIT since 2011, progressing from Research Fellow to his current professorship. He also serves as an Adjunct Professor at the University of Missouri and Theme Leader for Nanobiotechnology at RMIT’s Center for Advanced Materials and Industrial Chemistry. His teaching focuses on fostering student belonging and innovation in biotechnology education, including coordinating RMIT’s undergraduate Biotechnology program. Research Interests: His lab explores hybrid biomaterial synthesis, nano-enabled proteomics, and non-viral gene therapy using MOFs. Recent work emphasizes applications in diabetes biosensing, CRISPR/Cas9 delivery, and antimicrobial resistance mitigation through nanostrategies. Over 130+ publications and substantial research funding highlight his interdisciplinary impact. Professional Engagement: Editor roles in Frontiers in Bioengineering and Biotechnology , Co-Editor-in-Chief of Current Research in Nutrition and Food Science , and advisor to the Australasian Association of Ayurveda underscore his leadership. He actively mentors students in projects like nano-antimicrobial wound healing and aptamer-based hepatitis A detection. Key Achievements: Pioneered nucleic acid-encapsulated MOFs for cancer therapy and developed paper-based biosensors for rapid diagnostics. His work aligns with UN Sustainable Development Goals 2 (Zero Hunger) and 3 (Good Health).
Dr Emily Hewson is a Cancer Institute NSW Early Career Fellow and member of the Sydney School of Health Sciences at the University of Sydney's Faculty of Medicine and Health. Her research focuses on advancing real-time radiation therapy techniques, particularly in managing intrafraction motion for prostate and other cancers. She leads projects involving multileaf collimator (MLC) tracking, dose optimization, and deep learning integration in radiation oncology. Research interests include adaptive radiotherapy systems, kilovoltage intrafraction monitoring (KIM), and clinical trial implementation (e.g., TROG 15.01 SPARK trial). Her work emphasizes improving treatment accuracy through real-time dose-guided approaches and multitarget tracking for tumors with complex motion patterns. Developed experimental validations for MRI-linac integration and MLC tracking systems Authored a textbook chapter on Adaptive Radiation Therapy (ART) Recipient of Cancer Institute NSW Early Career Fellowship (2023) Recent grants include an AI platform for targeted radiotherapy (2024) and national critical infrastructure funding for lung cancer applications (2023). Her lab collaborates on real-time dose calculation algorithms and clinical trial implementation across multiple institutions.
João F. Mano is a Full Professor at the Department of Chemistry, University of Aveiro, and Director of the Doctoral Program on Biotechnology. He leads the COMPASS Research Group and serves as Vice-Director at CICECO - Aveiro Institute of Materials. His academic appointments include Invited Professor at University of Lorraine (France), Visiting Professor at KAIST (South Korea), and Adjunct Professor at Ajou University (South Korea). Education: PhD in Chemistry (1996, Technical University of Lisbon); D.Sc. in Tissue Engineering, Regenerative Medicine and Stem Cells (2012, University of Minho) Research Interests focus on Biomaterials for Regenerative Medicine , integrating Nanotechnology , Microtechnology , and Biofabrication . His group develops Bioinspired Materials using polymer chemistry, Decellularized Extracellular Matrix , and 3D Bioprinting to engineer Cell Microenvironments for therapeutic applications. Recent Publications highlight advancements in Human-Derived Hydrogels , Photopolymerizable Scaffolds , Magneto-Responsive Biomaterials , and Programmable Bioinks . Trends show emphasis on Organ-on-a-Chip integration, Smart Living Materials , and Green Bioprinting methodologies. Scientific Awards include: European Research Council Advanced Grants (2015, 2020) Fellow at IUPAC, European Academy of Sciences, and American Institute of Medical and Biological Engineering ERC Proof of Concept Grants Doctor Honoris Causa from University of Lorraine and Utrecht UNESCO Chair on Biomaterials George Winter Award (European Society for Biomaterials) Supervisions & Collaborations encompass 74+ MSc, 26+ PhD students, and 40+ postdocs. He co-founded METATISSUE and CELLULARIS Biomodels , and serves as Editor-in-Chief of Materials Today Bio .
Prof. Alexander Geissler holds the position of Full Professor of Health Care Management at the School of Medicine (Med-HSG) within the University of St. Gallen. His research focuses on health systems research, health economics, and health policy, with particular emphasis on digital transformation in healthcare and patient-reported outcomes. He has contributed extensively to studies on healthcare quality improvement, public reporting systems, and the integration of artificial intelligence in medical diagnostics and screening programs. His work spans topics like optimizing hospital digital maturity (e.g., German DigitalRadar project), analyzing surgical outcomes (robotic vs. open prostatectomies), and evaluating patient empowerment through quality information. He has pioneered methodologies for interpreting patient-reported outcomes (e.g., EQ-5D-3L) and designing clinical dashboards to enhance care delivery. Recent research highlights include investigating AI applications in breast cancer screening and cost-effectiveness of remote patient monitoring post-joint replacement surgery. Geissler’s publications demonstrate a strong focus on healthcare policy implications, such as hospital capacity planning, payment systems for specialized care, and cross-country comparisons of healthcare transparency initiatives. His work frequently bridges academic rigor with practical policy recommendations, particularly in Switzerland and Germany. Notably, he has addressed low-value care reduction, price sensitivity in healthcare demand, and the socio-demographic factors influencing healthcare utilization. While no specific awards are listed, his prolific research output reflects sustained leadership in health systems analysis. His academic contributions are disseminated through the Alexandria Research Platform and international peer-reviewed journals.
Dr. Stephanie Archer is an Associate Professor and Senior Research Associate at the University of Cambridge, jointly affiliated with the Department of Psychology and the Department of Public Health and Primary Care. Her work bridges psychological science with clinical applications, particularly in cancer risk assessment and digital health interventions. Dr. Archer holds a BSc, MSc, and PhD, though specific institutions are not mentioned in available sources. Her educational background has prepared her for interdisciplinary research at the intersection of psychology, public health, and clinical medicine. Her research focuses on three primary areas: designing multifactorial cancer risk prediction tools for clinical settings; exploring patient and staff experiences of health and social care; and developing/testing digital health interventions. She employs qualitative methods extensively while also engaging with quantitative approaches for comprehensive health services research. Her work demonstrates strong translational focus, moving from theoretical frameworks to practical clinical applications. Analysis of Dr. Archer's recent publications reveals a consistent trajectory in cancer risk prediction tools (particularly CanRisk), patient experience research across multiple conditions, and implementation science for digital health interventions. Her work spans breast, ovarian, prostate, and other cancers while also addressing mental health in autistic populations and patient safety in surgical settings. The interdisciplinary nature of her research connects psychology with oncology, primary care, and public health. Dr. Archer actively contributes to clinical guidelines development, as evidenced by her involvement in the Joint ABS-UKCGG-CanGene-CanVar consensus regarding CanRisk implementation. Her research methodology combines qualitative depth with mixed-methods approaches to address complex healthcare challenges. As a Senior Research Associate and Associate Professor, Dr. Archer likely supervises PhD students and early-career researchers, though specific advisees are not documented in available sources. Her teaching interests include health psychology, health services research, qualitative methods, and intervention development. Dr. Archer collaborates across multiple research units at Cambridge, including the Primary Care Unit and likely the Centre for Cancer Genetic Epidemiology, reflecting her interdisciplinary approach to improving cancer risk assessment and patient care pathways.
